Stereotactic ablative radiotherapy-driven immunosuppression is associated with poorer progression-free survival in cancer patients.

ABSTRACT:

Background

The landscape of cancer treatment has evolved rapidly within the last 50 years, and whilst radiotherapy, chemotherapy, and surgery remain the mainstay treatment options, there has been a shift towards using immunotherapy alone or in combination with other treatment modalities. There is an emerging paradigm that radiotherapy is immunogenic, driving stimulation of antigen-specific T cells capable of recognising tumour cells at distal sites to the treatment location.

Methods

Whole blood samples were collected from patients with primary and oligometastatic cancer before, during, and after treatment with stereotactic ablative radiotherapy (SABR). Using clinical full blood counts, multiparameter flow cytometry, Luminex, and ELISpot assays, this study explored the impact

SUBMITTER: Oliver J 

PROVIDER: S-EPMC12715060 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature